Doxazosin Mesylate Tablets

Pharmacological action Doxazosin tablets are long-acting α1-receptor blockers. This product selectively acts on postganglionic α1-adrenaline receptors, causing peripheral vasodilation, reducing peripheral vascular resistance and lowering blood pressure, with little effect on cardiac output. Like other α1-receptor blockers, doxazosin has a greater effect on standing blood pressure and heart rate. This product acts on the α1-adrenaline receptors of the prostate and bladder neck smooth muscles, relaxing the bladder neck, prostate, and prostate capsule smooth muscles, reducing urethral and bladder resistance, and thus alleviating urethral obstruction symptoms caused by prostate hyperplasia. This product can slightly reduce total cholesterol (2-3%), LDL-cholesterol (4%), and slightly increase HDL-cholesterol (4%).

The main ingredients of this product are: doxazosin mesylate. Molecular formula: C23H25N5O5CH4O3S Molecular weight: 547.59

This product is white or off-white tablets.

Essential hypertension; benign prostatic hyperplasia.

1. The usual dosage for adults is oral administration, with a starting dose of 1 mg once a day. The dosage is adjusted after 1-2 weeks based on clinical response and tolerance. The first dose and dosage adjustment should be taken before bedtime. The maintenance dose is 1-8 mg once a day, but more than 4 mg can easily cause postural hypotension. Foreign research data suggest that the maximum dosage of this product is 16 mg/day. 2. The dosage for children has not yet been determined.

1 Adverse reactions with an incidence of more than 10%: dizziness, headache, fatigue and discomfort. 2 Adverse reactions with an incidence of 2-10%: drowsiness, edema, nausea, rhinitis, dyspnea, postural hypotension, palpitations, vertigo, dry mouth, abnormal vision, nervousness, sexual dysfunction, diarrhea, polyuria, chest pain and body pain. Postural hypotension, edema and dyspnea are often dose-dependent. 3 Adverse reactions with an incidence of about 1%: arrhythmia, hypotension, rash, itching, joint pain/arthritis, muscle weakness, myalgia, paresthesia, movement disorders, ataxia, hypertonia, muscle spasm, flushing, conjunctivitis, tinnitus, depression, insomnia, constipation, indigestion, gastrointestinal flatulence, epistaxis, urinary incontinence, weakness and facial edema. 4 Adverse reactions with an incidence of about 1%: arrhythmia, hypotension, rash, itching, joint pain/arthritis, muscle weakness, myalgia, paresthesia, movement disorders, ataxia, hypertonia, muscle spasm, flushing, conjunctivitis, tinnitus, depression, insomnia, constipation, indigestion, gastrointestinal flatulence, epistaxis, urinary incontinence, weakness and facial edema.

1. Those who are allergic to quinazolines (such as prazosin, terazosin). 2. Those who develop severe hypotension after taking this product.

Precautions for children: As an antihypertensive drug, the safety and effectiveness of this product in children have not yet been determined. Precautions for pregnancy and lactation: The safety of this product for pregnant women has not yet been determined. This product can only be used in pregnant women when it is absolutely necessary. It is not yet known whether this drug can be secreted through human breast milk. Lactating women should use this drug with caution. Precautions for the elderly: This product may cause obvious hypotension reactions in elderly hypertensive patients, and the daily maintenance dose must be reduced. In the treatment of benign prostatic hyperplasia, the safety and effectiveness of this product are consistent in the elderly and non-elderly.

1. The use of indomethacin or other non-steroidal anti-inflammatory drugs with this product may weaken the antihypertensive effect. This may be due to the inhibition of renal prostaglandin synthesis and/or the retention of water and sodium. 2. Cimetidine can slightly increase the blood concentration and half-life of doxazosin, but its clinical significance is unknown. 3. When other antihypertensive drugs are used with this product, the antihypertensive effect is enhanced and the dose needs to be adjusted. 4. When estrogen is used in combination with this product, blood pressure increases due to fluid retention. 5. The combination of sympathomimetic amines with this product can weaken both the pressor effect of the former and the antihypertensive effect of the latter. 6. In vitro plasma studies have shown that doxazosin has no effect on the protein binding rate of digoxin, warfarin, phenytoin, and indomethacin.

Keep in airtight container and away from light.

2 mg (calculated as C23H25N5O5)

36 months.

Kangmei Pharmaceutical Co., Ltd.

• Founded in:

  1997-06-18

• Address:

  East side of Jieshen Road, Liusha, Puning City, Guangdong Province

• Tax NO.:

  91445200231131526C

• Registered Funds:

  13,863,866,690 yuan

• Website:

  Log in to view

• Email:

  Log in to view